Onconetix Inc (NASDAQ:ONCO) — Market Cap & Net Worth
Market Cap & Net Worth: Onconetix Inc (ONCO)
Onconetix Inc (NASDAQ:ONCO) has a market capitalization of $819.49K ($819.49K) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30318 globally and #5887 in its home market, demonstrating a -4.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Onconetix Inc's stock price $0.64 by its total outstanding shares 1555015 (1.56 Million). Analyse Onconetix Inc operating cash flow efficiency to see how efficiently the company converts income to cash.
Onconetix Inc Market Cap History: 2022 to 2026
Onconetix Inc's market capitalization history from 2022 to 2026. Data shows change from $68.42 Million to $987.43K (-85.78% CAGR).
Index Memberships
Onconetix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #910 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2880 of 3165 |
Weight: Onconetix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Onconetix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Onconetix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.39x
Onconetix Inc's market cap is 0.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $12.32 Million | $58.47K | -$37.41 Million | 210.65x | N/A |
| 2024 | $979.66K | $2.52 Million | -$58.69 Million | 0.39x | N/A |
Competitor Companies of ONCO by Market Capitalization
Companies near Onconetix Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Onconetix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Onconetix Inc Historical Marketcap From 2022 to 2026
Between 2022 and today, Onconetix Inc's market cap moved from $68.42 Million to $ 987.43K, with a yearly change of -85.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $987.43K | -59.29% |
| 2025 | $2.43 Million | +147.62% |
| 2024 | $979.66K | -92.05% |
| 2023 | $12.32 Million | -82.00% |
| 2022 | $68.42 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Onconetix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $819.49K USD |
| MoneyControl | $819.49K USD |
| MarketWatch | $819.49K USD |
| marketcap.company | $819.49K USD |
| Reuters | $819.49K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other prod… Read more